164 related articles for article (PubMed ID: 29063359)
1. Heparin, coumarin, protein C, antithrombin, fibrinolysis and other clotting related resistances: old and new concepts in blood coagulation.
Girolami A; Cosi E; Ferrari S; Girolami B
J Thromb Thrombolysis; 2018 Jan; 45(1):135-141. PubMed ID: 29063359
[TBL] [Abstract][Full Text] [Related]
2. A new global test for the evaluation of the activated factor II-antithrombin system.
Preda L; Figini S; Rossi E
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):405-10. PubMed ID: 11505085
[TBL] [Abstract][Full Text] [Related]
3. New data on FII, FV, FIX and thrombomodulin defects: blood keeps clotting in normal and in peculiar ways.
Girolami A; Ferrari S; Girolami B; Randi ML
Hematology; 2019 Dec; 24(1):232-237. PubMed ID: 31793409
[No Abstract] [Full Text] [Related]
4. New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice.
Girolami A; Cosi E; Ferrari S; Lombardi AM; Girolami B
J Thromb Thrombolysis; 2017 Jul; 44(1):71-75. PubMed ID: 28251495
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
Petăjă J; Peltola K; Sairanen H; Leijala M; Kekomäki R; Vahtera E; Siimes MA
J Thorac Cardiovasc Surg; 1996 Sep; 112(3):665-71. PubMed ID: 8800154
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation.
Takagi Y; Kato I; Ando Y; Nakamura Y; Murata M; Takagi A; Murate T; Kojima T
Thromb Res; 2014 Oct; 134(4):914-7. PubMed ID: 25149909
[TBL] [Abstract][Full Text] [Related]
7. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
8. [Antithrombin resistance: a new mechanism of inherited thrombophilia].
Kojima T; Takagi A; Murata M; Takagi Y
Rinsho Ketsueki; 2015 Jun; 56(6):632-8. PubMed ID: 26256872
[TBL] [Abstract][Full Text] [Related]
9. The thrombophilic state in cancer patients.
Gouin-Thibault I; Achkar A; Samama MM
Acta Haematol; 2001; 106(1-2):33-42. PubMed ID: 11549775
[TBL] [Abstract][Full Text] [Related]
10. Thrombophilia as a multigenic disease.
Zöller B; García de Frutos P; Hillarp A; Dahlbäck B
Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
[TBL] [Abstract][Full Text] [Related]
11. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
[TBL] [Abstract][Full Text] [Related]
12. Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance.
Takagi Y; Murata M; Kozuka T; Nakata Y; Hasebe R; Tamura S; Takagi A; Matsushita T; Saito H; Kojima T
Thromb Haemost; 2016 Nov; 116(6):1022-1031. PubMed ID: 27604259
[TBL] [Abstract][Full Text] [Related]
13. Laboratory investigation of hypercoagulability.
Francis JL
Semin Thromb Hemost; 1998; 24(2):111-26. PubMed ID: 9579632
[TBL] [Abstract][Full Text] [Related]
14. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
[TBL] [Abstract][Full Text] [Related]
15. Chromogenic substrate (S-2238) prothrombin assay in prothrombin deficiencies and abnormalities. Lack of identity with clotting assays in congenital dysprothrombinemias.
Girolami A; Patrassi G; Toffanin F; Saggin L
Am J Clin Pathol; 1980 Jul; 74(1):83-7. PubMed ID: 7395819
[TBL] [Abstract][Full Text] [Related]
16. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function.
Adams MJ; Irish AB; Watts GF; Oostryck R; Dogra GK
Thromb Res; 2008; 123(2):374-80. PubMed ID: 18486198
[TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
18. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
19. Hypercoagulable states: molecular genetics to clinical practice.
Schafer AI
Lancet; 1994 Dec 24-31; 344(8939-8940):1739-42. PubMed ID: 7997003
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
Meddahi S; Bara L; Fessi H; Samama MM
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
